FIELD: pharmacology.
SUBSTANCE: inventions relate to a peptide synthesized chemically or genetically engineered, compositions comprising such a peptide, DNA coding a polypeptide, vector incorporating such a DNA, a host cell for expression of the peptide, a peptide screening Kit, capable of suppressing a respiratory virus infection and a method for screening of a peptide capable of suppressing a respiratory virus infection. The presented peptide contains 5 or more essential amino acids, 2 or more of these essential amino acids are located in the N-terminal or C-terminal region, and the N-terminal region contains a sequence of no more than 10 amino acids from the peptide N-terminal amino acid and the C-terminal region contains a sequence of no more than 10 amino acids from the peptide C-terminal amino acid, while the peptide consists of a sequence of amino acids, at least 90% identical to SEQ ID NO: 10.
EFFECT: possibility of application of inventions to block infections of respiratory viruses such as influenza viruses or coronaviruses in the target cells for prevention and treatment of these infections.
23 cl, 10 dwg, 3 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIVIRAL COMPOSITION | 2020 |
|
RU2740660C1 |
ANTIVIRAL COMPOSITION | 2020 |
|
RU2740657C1 |
AGENT WITH ANTIVIRAL ACTIVITY AGAINST INFLUENZA A AND SARS-CoV-2 VIRUSES | 2022 |
|
RU2796748C1 |
METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS | 2021 |
|
RU2746362C1 |
ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
MEFLOQUINE AND COMBINATIONS THEREOF FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | 2020 |
|
RU2763024C1 |
METHOD FOR PRODUCING PROPHYLACTIC ANTIVIRAL COMPOSITION BASED ON EPIGALLOCATECHIN-3-GALLATE (EGCG) | 2021 |
|
RU2771898C1 |
RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
Authors
Dates
2017-12-21—Published
2014-02-19—Filed